Allopurinol for chronic gout

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Seth, Rakhi ^a   Kydd, Alison S R ^b   Buchbinder, Rachelle ^c   Bombardier, Claire ^d   Edwards, Christopher J ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MONASH UNIVERSITY   (Australia)

^d INSTITUTE FOR WORK AND HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; FEBUXOSTAT; PLACEBO; PROBENECID; URATE; ANTIGOUT AGENT; THIAZOLE DERIVATIVE; URIC ACID;

DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; GOUT; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; BLOOD; CHRONIC DISEASE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALLOPURINOL; BENZBROMARONE; CHRONIC DISEASE; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; PROBENECID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; URIC ACID;

EID: 84921446313     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006077.pub3     Document Type: Review

References (79)

1. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine 2005;353(23):2450-61.
2. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy 2010;12(2):R63.
3. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology 1989;16(9):1246-48.
4. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases 1982;41(1):59-65.
5. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology 1999;5(2):49-55.
6. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Annals of the Rheumatic Diseases 2009;68(6):892-7.
7. Rodnan GP, Robin JA, Tolchin SF, Elion GB. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA 1975;231(11):1143-7.
8. Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis and Rheumatism 2008;59(11):1540-8.
9. Scott JT. Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases 1966;25(6 Suppl):623-6.
10. Singal KK, Goyal S, Gupta P, Aggawal BK. Comparison between allopurinol and febuxostat in management of gout patients - a prospective study. Bangladesh Journal of Medical Science 2011;10:257-9.
11. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine 2012;125(11):1126-34.
12. Akkasilpa S, Osiri M, Deesomchok U, Avihingsanon Y. The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia. Journal of the Medical Association of Thailand 2004;87(9):1087-91.
13. Akram M, Mohiuddin E, Hannan A, Usmanghani K. Comparative study of herbal medicine with allopathic medicine for the treatment of hyperuricemia. Journal of Pharmacognosy and Phytotherapy 2010;2(6):86-90.
14. Auscher C, Amor B, Brouilhet H, Pasquier C, Delbarre F. Effect of allopurinol in gouty patients given long term corticotherapy. Biomedicine 1974;21(11):448-51.
15. Berg H. Effectiveness and tolerance of long-term uricosuric treatment [in German]. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1990;45(23):719-20.
16. Bowie EA, Simmonds HA, North JD. Allopurinol in treatment of patients with gout and chronic renal failure. New Zealand Medical Journal 1967;66(421):606-11.
17. Bresnik W, Heiter H, Mertz DP, Holler HD, Lang PD, Vollmar J. Uric acid lowering effect of allopurinol (300 mg) in single or in fractionated dosage [Vergleich der harnsauresenkenden wirkung von 300 mg allopurinol bei einmaliger und fraktionierter gabe]. Therapiewoche 1975;25(36):4862-4.
18. Brewis I, Ellis RM, Scott JT. Single daily dose of allopurinol. Annals of the Rheumatic Diseases 1975;34(3):256-9.
19. Chou CT, Kuo SC. The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol. American Journal of Chinese Medicine 1995;23(3-4):261-71.
20. Emmerson BT, Hazelton RA, Whyte IM. Comparison of the urate lowering effects of allopurinol and diflunisal. Journal of Rheumatology 1987;14(2):335-7.
21. Fraser RC, Davis RH, Walker FS. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. Journal of the Royal College of General Practitioners 1987;37(302):409-11.
22. Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis and Rheumatism 1966;9(3):414-23.
23. Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. Journal of the Medical Association of Thailand 2002;85(Suppl 1):40-7.
24. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Toshitaka N, et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. Journal of Clinical Rheumatology 2011;17(4 Suppl 2):S44-9.
25. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. Journal of Clinical Rheumatology 2011;17(4 Suppl 2):S13-8.
26. Kawenoki-Minc E, Eyman E, Sopata I, Werynska-Przybylska J. The influence of allopurinol on the course of gout. A study of 28 cases. Reumatologia 1970;8(3):177-92.
27. Kersley GD. Allopurinol in primary gout with and after the administration of uricosuric agents. Annals of the Rheumatic Diseases 1966;25(6 Suppl):643-4.
28. Kuzell WC, Seebach LM, Glover RP, Jackman AE. Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone. Annals of the Rheumatic Diseases 1966;25(6 Suppl):634-42.
29. Matzkies F. Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia [Lang anhaltende Normalisierung der Harnsaure nach einer Kombinations-therapie mit 300mg Allopurinol and 60mg Benzbromaron bei Patienten mit Gicht und Hyperurikamie]. Medizinische Klinik 1992;87(9):460-2.
30. Mituszova L, Erdely E, Benyai B. Use of milurit in the treatment of gout. Therapia Hungarica 1973;21(3-4):111-3.
31. Muller FO, Schall R, Groenewoud G, Hundt HKL, Van der Merwe JC, Van Dyk M. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. European Journal of Clinical Pharmacology 1993;44(1):69-72.
32. O'Duffy JD, Scherbel AL. Treatment of gout and urate calculi with allopurinol. Cleveland Clinic Quarterly 193;35(3):145-54.
33. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. Journal of Clinical Rheumatology 2008;14(1):6-11.
34. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Annals of the Rheumatic Diseases 1998;57(9):545-9.
35. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis and Rheumatism 2002;47(4):356-60.
36. Qiu R, Shen R, Lin D, Chen Y, Ye H. Treatment of 60 cases of gouty arthritis with modified Simiao Tang. Journal of Traditional Chinese Medicine 2008;28(2):94-7.
37. Radak-Perovic M, Zlatkovic-Svenda M. The efficacy and tolerability of allopurinol dose escalation in patients with gout [in Serbian]. Srpski Arhiv za Celokupno Lekarstvo 2013;141(5-6):333-6.
38. Reinders M, van Roon E, Houtman P, Brouwers J, Jansen T. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clinical Rheumatology 2007;26(9):1459-65.
39. Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Annals of the Rheumatic Diseases 2009;68(1):51-6.
40. Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical Pharmacology & Therapeutics 2011;90(3):392-8.
41. Stamp LK, O'Donnell JL, Zhang MJ, Frampton C, Barclay ML, Chapman PT. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis and Rheumatism 2011;63(2):412-21.
42. Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clinical Pharmacokinetics 2008;47(2):111-8.
43. Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. Journal of Rheumatology 2011;38(5):904-10.
44. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Annals of the Rheumatic Disease 2003;62:572-5.
45. Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. British Journal of Clinical Practice 1982;36(10):353-8.
46. Zöllner N, Schattenkirchner M. Allopurinol in the treatment of gout and uric acid nephrolithiasis. Deutsche Medizinische Wochenschrift 1967;92(14):654-60.
47. Kumar B, Agarawal PK. Comparative evaluation of efficacy and safety profile of febuxostat with allopurinol in patients with hyperuricaemia and chronic gout. International Journal of Pharma Medicine and Biological Sciences 2013;2(4):52-6.
48. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout. Journal of Rheumatology 2009;36(6):1273-82.
49. Busquets N, Carmona L, Suris X. Systematic review: safety and efficacy of anti-TNF in elderly patients. Rheumatologica Clinica 2011;7(2):104-12.
50. Cates C. Visual Rx Version 3. www.nntonline.net/visualrx (accessed 3 September 2014).
51. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety and efficacy for hyperuricaemia in gout. Current Rheumatology Reports 2009;11(2):135-40.
52. Chohan S, Becker MA. Update on emerging urate lowering therapies. Current Opinion in Rheumatology 2009;21(2):143-9.
53. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Seminars in Dialysis 2007;20(5):391-5.
54. Dalbeth N, Schauer C, MacDonald P, Perez-Ruiz F, Schumacher HR, Hamburger S. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Annals of the Rheumatic Diseases 2011;70(4):597-604.
55. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
56. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis and Rheumatism 2001;44(1):231-8.
57. Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Seminars in Arthritis and Rheumatism 2013;43:367-75.
58. Gibson T, Simmonds HA, Potter C, Rogers V. A controlled study of the effect of long term allopurinol treatment on renal function in gout. Advances in Experimental Medicine and Biology 1980;122(A):257-62.
59. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. Recommendations for the diagnosis and management of gout and hyperuricaemia. Postgraduate Medicine 2011;163(6):3-36.
60. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Annals of the Rheumatic Diseases 2006;65(10):1368-72.
61. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
62. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
63. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
64. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46(8):1372-4.
65. Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh A, Terkeltaub R, et al. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology 2011;50(7):1331-6.
66. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Research 2012;64(10):1431-46.
67. Klippel JH, Dieppe PA, Brooks P, Carette S, Dequeker J, Gerber LH, et al. Rheumatology. London: Mosby, 1994.
68. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
69. Schlesinger N. Management of acute and chronic gouty arthritis. Drugs 2004;64(21):2399-416.
70. Schumacher HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst D, et al. Outcome measures for acute and chronic gout. Proceedings of OMERACT 7; 2004 May 8-12; Asilomar (CA).
71. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcomes domains for studies of acute and chronic gout. Journal of Rheumatology 2009;36(10):2342-5.
72. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
73. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
74. Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. Journal of Rheumatology 2011;38(7):1452-7.
75. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
76. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism 1977;20:895-900.
77. Wallace SL, Singer JZ. Therapy in gout. Rheumatic Diseases Clinics of North America 1988;14(2):441-57.
78. Wortmann RL. Gout and hyperuricaemia. Current Opinion in Rheumatology 2002;14(3):281-6.
79. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases 2006;65:1312-24.